Related references
Note: Only part of the references are listed.AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
Stacey Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)
Ian Chau et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer
Chinthalapally V. Rao et al.
CARCINOGENESIS (2017)
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
Joleen M. Hubbard et al.
TARGETED ONCOLOGY (2017)
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality
Andreas Pircher et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
Konstantinos Katsanos et al.
PLOS ONE (2017)
A molecular portrait of microsatellite instability across multiple cancers
Isidro Cortes-Ciriano et al.
NATURE COMMUNICATIONS (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors
M. J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).
M. Kozloff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Effects of a combination of antiangiogenic and antilymphangiogenic therapies on a death receptor-5 mediated antitumor immunotherapy in mice.
Yoko Tsukita et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
Simon Chowdhury et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features
Fukiko Kawai-Kitahata et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer
A. Blythe Ryerson et al.
CANCER (2016)
Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)
J. Bendell et al.
EUROPEAN JOURNAL OF CANCER (2016)
Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003
Arkadiusz Z. Dudek et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Genetic alterations in hepatocellular carcinoma: An update
Zhao-Shan Niu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
Ahmed O. Kaseb et al.
ONCOTARGETS AND THERAPY (2016)
Telomere and Telomerase Therapeutics in Cancer
Yucheng Xu et al.
GENES (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Andrew H. Ko et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT plus TMZ vs RT plus nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant).
Erica Hlavin Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Global Epidemiology of Hepatocellular Carcinoma An Emphasis on Demographic and Regional Variability
Katherine A. McGlynn et al.
CLINICS IN LIVER DISEASE (2015)
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
p53 gene therapy-based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study
Ai Shen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Toward understanding and exploiting tumor heterogeneity
Ash A. Alizadeh et al.
NATURE MEDICINE (2015)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Gabriela M. Baerlocher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer
A. A. Chiappori et al.
ANNALS OF ONCOLOGY (2015)
The mutational landscape of hepatocellular carcinoma
Ju-Seog Lee
CLINICAL AND MOLECULAR HEPATOLOGY (2015)
Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma
Atsushi Takai et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
N. A. Rizvi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Detection of Recurrent Prostate Cancer After Radical Prostatectomy: Comparison of 11C-Choline PET/CT with Pelvic Multiparametric MR Imaging with Endorectal Coil
Kazuhiro Kitajima et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Yasushi Totoki et al.
NATURE GENETICS (2014)
Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma
Manoj Kumar et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2014)
Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma
Rangaswamy Govindarajan et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Advances in adenovirus-mediated p53 cancer gene therapy
Hiroshi Tazawa et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Zhengyan Kan et al.
GENOME RESEARCH (2013)
Identification of Driver Genes in Hepatocellular Carcinoma by Exome Sequencing
Sean P. Cleary et al.
HEPATOLOGY (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs
Floriane Pez et al.
JOURNAL OF HEPATOLOGY (2013)
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
Chih-Hung Hsu et al.
ONCOLOGY (2013)
Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial
Steven Robert Alberts et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
Philip A. Philip et al.
CANCER (2012)
Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells
Y. Watanabe et al.
CANCER GENE THERAPY (2012)
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
Thomas Yau et al.
INVESTIGATIONAL NEW DRUGS (2012)
Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial
A. O. Kaseb et al.
ONCOLOGY (2012)
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
Austin Gurney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study
Giuseppe Cabibbo et al.
WORLD JOURNAL OF HEPATOLOGY (2012)
Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines
Atsuko Sakakibara et al.
AURIS NASUS LARYNX (2011)
Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma
P. K. H. Chow et al.
BRITISH JOURNAL OF CANCER (2011)
Phase 2 Trial of Bevacizumab, Capecitabine, and Oxaliplatin in Treatment of Advanced Hepatocellular Carcinoma
Weijing Sun et al.
CANCER (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
Jon Amund Kyte et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma
Sarah Beseme Nambotin et al.
JOURNAL OF HEPATOLOGY (2011)
p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up
Yong-Song Guan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
Tim F. Greten et al.
BMC CANCER (2010)
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
C-H Hsu et al.
BRITISH JOURNAL OF CANCER (2010)
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
Ghassan K. Abou-Alfa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma
Zhi-xiang Yang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
John Nemunaitis et al.
MOLECULAR THERAPY (2010)
Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial
Geng Tian et al.
ANTI-CANCER DRUGS (2009)
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma - Results of a multicenter phase 2 study
Amani Asnacios et al.
CANCER (2008)
Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model
P. Huang et al.
CANCER GENE THERAPY (2008)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A small-molecule inhibitor of Tcf/β-catenin signaling down-regulates PPARγ and PPARδ activities
Shlomo Handeli et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway
Yu-Lueng Shih et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Melanie B. Thomas et al.
CANCER (2007)
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
Andrew X. Zhu et al.
CANCER (2007)
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) -: Results of a phase II study
Samy Louafi et al.
CANCER (2007)
P53 gene in treatment of hepatic carcinoma:: Status quo
Yong-Song Guan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Paal F. Brunsvig et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
AX Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early-stage hepatocellular carcinoma in patients with cirrhosis: Long-term results of percutaneous image-guided radiofrequency ablation
R Lencioni et al.
RADIOLOGY (2005)
Telomerase-specific replication-selective virotherapy for human cancer
T Kawashima et al.
CLINICAL CANCER RESEARCH (2004)
High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial
PKH Chow et al.
HEPATOLOGY (2002)
Share Paper
